Continuous Long-Term Entecavir Therapy in Naïve Chronic Hepatitis B Patients Showing Partial Virologic Response
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: We investigated the efficacy of continuous long-term entecavir 0.5 mg treatment in naïve chronic hepatitis B patients showing a partial virologic response (PVR). Methods: A total of 227 patients were included. PVR was defined as a more than 1 log10 IU/mL decline in detectable serum hepatitis B virus (HBV) DNA by polymerase chain reaction (PCR; ≥20 IU/mL) at week 48. A complete virologic response (CVR) was defined as undetectable serum HBV DNA by PCR (<20 IU/mL) at week 48. Results: At week 48,the rate of the PVR was 64/227 (28.2%). Among patients with PVR, the cumulative rates of virologic response (serum HBV DNA <20 IU/mL) at weeks 96 and 144 were 45.2%and 73.8%, respectively. The cumulative rates of genotypic resistance were not significantly different between patients with a PVR and patients with a CVR (p=0.057). However, the cumulative rates of virologic breakthrough were higher in patients with PVR than in patients with CVR (4% vs 0% and 11.2% vs 0% at weeks 96 and 144, respectively; p<0.001). Conclusions: Long-term continuous entecavir 0.5 mg treatment in patients with a PVR resulted in an additional virologic response without a significant increase in genotypic resistance. However, the rate of virologic breakthrough was higher in the partial responders.
Abstract
Background/Aims: We investigated the efficacy of continuous long-term entecavir 0.5 mg treatment in naïve chronic hepatitis B patients showing a partial virologic response (PVR). Methods: A total of 227 patients were included. PVR was defined as a more than 1 log10 IU/mL decline in detectable serum hepatitis B virus (HBV) DNA by polymerase chain reaction (PCR; ≥20 IU/mL) at week 48. A complete virologic response (CVR) was defined as undetectable serum HBV DNA by PCR (<20 IU/mL) at week 48. Results: At week 48,the rate of the PVR was 64/227 (28.2%). Among patients with PVR, the cumulative rates of virologic response (serum HBV DNA <20 IU/mL) at weeks 96 and 144 were 45.2%and 73.8%, respectively. The cumulative rates of genotypic resistance were not significantly different between patients with a PVR and patients with a CVR (p=0.057). However, the cumulative rates of virologic breakthrough were higher in patients with PVR than in patients with CVR (4% vs 0% and 11.2% vs 0% at weeks 96 and 144, respectively; p<0.001). Conclusions: Long-term continuous entecavir 0.5 mg treatment in patients with a PVR resulted in an additional virologic response without a significant increase in genotypic resistance. However, the rate of virologic breakthrough was higher in the partial responders.
참고문헌 (18)
- European Association For The Study of The Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Korean Association for the Study of the Liver, "KASL Clinical Practice Guidelines: management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
- Zoulim F, "Management of treatment failure in chronic hepatitis B", J Hepatol, 56(Suppl 1), pp.S112~S122 (2012)
- Yuen MF, "Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy", Hepatology, 34(4 Pt 1), pp.785~791 (2001)
- Hadziyannis SJ, "Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years", Gastroenterology, 131, pp.1743~1751 (2006)
- Liaw YF, "2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B", GASTROENTEROLOGY, 136, pp.486~495 (2009), W B SAUNDERS CO-ELSEVIER INC
- Chang TT, "A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B", N Engl J Med, 354, pp.1001~1010 (2006)
- Lai CL, "Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B", N Engl J Med, 354, pp.1011~1020 (2006)
- Tenney DJ, "Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy", Hepatology, 49, pp.1503~1514 (2009)
- Osborn M, "Safety and efficacy of entecavir for the treatment of chronic hepatitis B", Infect Drug Resist, 4, pp.55~64 (2011)
- Han KH, "Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B", ANTIVIRAL THERAPY, 16(1), pp.77~87 (2011)
- Heo J, "A 96-week randomized trial of switching to entecavir in chronic hepatitis B patients with a partial virological response to lamivudine", ANTIVIRAL THERAPY, 17(8), pp.1563~1570 (2012)
- Reijnders JG, "Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues", J Hepatol, 52, pp.493~500 (2010)
- European Association For The Study of The Liver, "EASL Clinical Practice Guidelines: management of chronic hepatitis B", J Hepatol, 50, pp.227~242 (2009)
- Chon YE, "Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B", ANTIVIRAL THERAPY, 16(4), pp.469~477 (2011)
- Zoutendijk R, "Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response", Hepatology, 54, pp.443~451 (2011)
- Ko SY, "Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 47(11), pp.1362~1367 (2012), INFORMA HEALTHCARE
- Pan CQ, "Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir", J Viral Hepat, 19, pp.213~219 (2012)